FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2119582011> ?p ?o ?g. }

• W2119582011 abstract "There is an urgent need to develop and test novel compounds against malaria infection. Carrageenans, sulphated polysaccharides derived from seaweeds, have been previously shown to inhibit Plasmodium falciparum in vitro. However, they are inflammatory and alter the permeability of the blood-brain barrier, raising concerns that their use as a treatment for malaria could lead to cerebral malaria (CM), a severe complication of the disease. In this work, the authors look into the effects of the administration of λ-carrageenan to the development and severity of CM in BALB/c mice, a relatively non-susceptible model, during infection with the ANKA strain of Plasmodium berghei.Five-week-old female BALB/c mice were infected with P. berghei intraperitoneally. One group was treated with λ-carrageenan (PbCGN) following the 4-day suppressive test protocol, whereas the other group was not treated (PbN). Another group of healthy BALB/c mice was similarly given λ-carrageenan (CGN) for comparison. The following parameters were assessed: parasitaemia, clinical signs of CM, and mortality. Brain and other vital organs were collected and examined for gross and histopathological lesions. Evans blue dye assays were employed to assess blood-brain barrier integrity.Plasmodium berghei ANKA-infected BALB/c mice treated with λ-carrageenan died earlier than those that received no treatment. Histopathological examination revealed that intracerebral haemorrhages related to CM were present in both groups of infected BALB/c mice, but were more numerous in those treated with λ-carrageenan than in mock-treated animals. Inflammatory lesions were also observed only in the λ-carrageenan-treated mice. These observations are consistent with the clinical signs associated with CM, such as head tilt, convulsions, and coma, which were observed only in this group, and may account for the earlier death of the mice.The results of this study indicate that the administration of λ-carrageenan exacerbates the severe brain lesions and clinical signs associated with CM in BALB/c mice infected with P. berghei ANKA." @default.
• W2119582011 created "2016-06-24" @default.
• W2119582011 creator A5004281945 @default.
• W2119582011 creator A5022421433 @default.
• W2119582011 creator A5031532845 @default.
• W2119582011 creator A5035465590 @default.
• W2119582011 creator A5038261849 @default.
• W2119582011 creator A5039349212 @default.
• W2119582011 creator A5052114119 @default.
• W2119582011 creator A5074790060 @default.
• W2119582011 creator A5081128491 @default.
• W2119582011 creator A5085099174 @default.
• W2119582011 creator A5087867222 @default.
• W2119582011 creator A5089293101 @default.
• W2119582011 date "2014-12-01" @default.
• W2119582011 modified "2023-10-12" @default.
• W2119582011 title "Lambda-carrageenan treatment exacerbates the severity of cerebral malaria caused by Plasmodium berghei ANKA in BALB/c mice" @default.
• W2119582011 cites W111833607 @default.
• W2119582011 cites W1855353753 @default.
• W2119582011 cites W1888908820 @default.
• W2119582011 cites W1966399595 @default.
• W2119582011 cites W1970480941 @default.
• W2119582011 cites W1985660628 @default.
• W2119582011 cites W1990331189 @default.
• W2119582011 cites W1993655373 @default.
• W2119582011 cites W2003784891 @default.
• W2119582011 cites W2005757619 @default.
• W2119582011 cites W2008727251 @default.
• W2119582011 cites W2021821141 @default.
• W2119582011 cites W2027639382 @default.
• W2119582011 cites W2033657115 @default.
• W2119582011 cites W2036354613 @default.
• W2119582011 cites W2082450214 @default.
• W2119582011 cites W2108997420 @default.
• W2119582011 cites W2112060174 @default.
• W2119582011 cites W2112356892 @default.
• W2119582011 cites W2121714223 @default.
• W2119582011 cites W2122202442 @default.
• W2119582011 cites W2122893358 @default.
• W2119582011 cites W2124439764 @default.
• W2119582011 cites W2125468126 @default.
• W2119582011 cites W2149093163 @default.
• W2119582011 cites W2158953607 @default.
• W2119582011 cites W2159031978 @default.
• W2119582011 cites W2162803373 @default.
• W2119582011 doi "https://doi.org/10.1186/1475-2875-13-487" @default.
• W2119582011 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4295290" @default.
• W2119582011 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25495520" @default.
• W2119582011 hasPublicationYear "2014" @default.
• W2119582011 type Work @default.
• W2119582011 sameAs 2119582011 @default.
• W2119582011 citedByCount "9" @default.
• W2119582011 countsByYear W21195820112017 @default.
• W2119582011 countsByYear W21195820112020 @default.
• W2119582011 countsByYear W21195820112022 @default.
• W2119582011 countsByYear W21195820112023 @default.
• W2119582011 crossrefType "journal-article" @default.
• W2119582011 hasAuthorship W2119582011A5004281945 @default.
• W2119582011 hasAuthorship W2119582011A5022421433 @default.
• W2119582011 hasAuthorship W2119582011A5031532845 @default.
• W2119582011 hasAuthorship W2119582011A5035465590 @default.
• W2119582011 hasAuthorship W2119582011A5038261849 @default.
• W2119582011 hasAuthorship W2119582011A5039349212 @default.
• W2119582011 hasAuthorship W2119582011A5052114119 @default.
• W2119582011 hasAuthorship W2119582011A5074790060 @default.
• W2119582011 hasAuthorship W2119582011A5081128491 @default.
• W2119582011 hasAuthorship W2119582011A5085099174 @default.
• W2119582011 hasAuthorship W2119582011A5087867222 @default.
• W2119582011 hasAuthorship W2119582011A5089293101 @default.
• W2119582011 hasBestOaLocation W21195820111 @default.
• W2119582011 hasConcept C203014093 @default.
• W2119582011 hasConcept C2776529007 @default.
• W2119582011 hasConcept C2777237215 @default.
• W2119582011 hasConcept C2778048844 @default.
• W2119582011 hasConcept C2778371730 @default.
• W2119582011 hasConcept C2781227287 @default.
• W2119582011 hasConcept C2908793570 @default.
• W2119582011 hasConcept C71924100 @default.
• W2119582011 hasConcept C86803240 @default.
• W2119582011 hasConcept C8891405 @default.
• W2119582011 hasConcept C98274493 @default.
• W2119582011 hasConceptScore W2119582011C203014093 @default.
• W2119582011 hasConceptScore W2119582011C2776529007 @default.
• W2119582011 hasConceptScore W2119582011C2777237215 @default.
• W2119582011 hasConceptScore W2119582011C2778048844 @default.
• W2119582011 hasConceptScore W2119582011C2778371730 @default.
• W2119582011 hasConceptScore W2119582011C2781227287 @default.
• W2119582011 hasConceptScore W2119582011C2908793570 @default.
• W2119582011 hasConceptScore W2119582011C71924100 @default.
• W2119582011 hasConceptScore W2119582011C86803240 @default.
• W2119582011 hasConceptScore W2119582011C8891405 @default.
• W2119582011 hasConceptScore W2119582011C98274493 @default.
• W2119582011 hasIssue "1" @default.
• W2119582011 hasLocation W21195820111 @default.
• W2119582011 hasLocation W21195820112 @default.
• W2119582011 hasLocation W21195820113 @default.
• W2119582011 hasLocation W21195820114 @default.
• W2119582011 hasOpenAccess W2119582011 @default.
• W2119582011 hasPrimaryLocation W21195820111 @default.
• W2119582011 hasRelatedWork W2039976430 @default.

• next